Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Oral Immunotherapy for Children With Peanut Allergy: A Randomized Controlled Trial

NCT07895095 is registered in ClinicalTrials.gov with Laura Ozer Kettner as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07895095 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
Oral Immunotherapy for Children With Peanut Allergy: A Randomized Controlled Trial
Lead sponsor
Laura Ozer Kettner
Phase
Not applicable
Overall status
Not yet recruiting
Start date
October 31, 2026
Completion date
October 31, 2031
Enrollment
56 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

food allergies, food allergy in children, food allergy peanut, peanut allergic subjects, peanut allergies, peanut hypersensitivity

Arms

As registered; 2 arms.

  • Oral immunotherapy ExperimentalOral immunotherapy with peanut

    Children randomized to oral immunotherapy will ingest a daily dose of peanut. Dose escalation will be performed approximately every two weeks at the allergy clinic or via online consultations. After approximately 6 months, a maintenance dose of 300 mg food protein will be reached and continued daily for 6-12 months.

  • Avoidance No intervention

    Children randomized to avoidance will receive standard care for peanut allergy, namely avoidance of peanut.

Primary endpoints

Registered primary outcome measures; 1 primary.

  • Tolerance to peanut (4000 mg) 1-1.5 years after enrollment

    Proportion of children who tolerate a cumulative dose of 4000 mg of peanut protein at an oral food challenge

Lead sponsor's other trials

Laura Ozer Kettner, most recent start first.

Similar trials

Same condition (Peanut Hypersensitivity) and phase, most recent start first.